EMEA-001071-PIP02-12-M02
Key facts
| Invented name |
Cimzia
|
| Active substance |
Certolizumab pegol
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0192/2017
|
| PIP number |
EMEA-001071-PIP02-12-M02
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
UCB Pharma S.A.
E-mail: ucbcares.uk@ucb.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|